Furthermore, morphological data from radiographic scans of tumor response demonstrated a distinctive and characteristic feature of potent antiangiogenic activity from treatment with telatinib, verifying the on-target effect of the medication. Positive interim results of the Phase 2 trial of telatinib with mixture chemotherapy for first-collection treatment of metastatic tummy cancer patients, a very difficult to treat population, in October 2010 and demonstrated fast onset of objective tumor responses in two-thirds of the treated patients were reported. We are very pleased that further analysis of the telatinib Phase 2 data confirms the potent mechanism-based activity of telatinib.D., chief operating and scientific officer, ACT Biotech.September 30 In the three quarters finished, 2010, Akorn recognized $1.9 million in revenue and around $2.0 million in altered EBITDA as a total result of its participation in the Akorn-Strides LLC joint venture. Raj Rai, Chief Executive Officer, commented, That is a positive outcome for Akorn as the proceeds from the sale provide us with immediate access to capital to accelerate our infrastructure improvements, pursue acquisitions and in-licensing of niche pharmaceuticals, along with strengthen our balance sheet. We would like to thank our joint venture partner, Strides, for assisting build value inside our joint venture which includes led to a mutually helpful strategic outcome.